First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. First BEAT (Bevacizumab Expanded Access Trial).

Trial Profile

First-line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum. First BEAT (Bevacizumab Expanded Access Trial).

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Jan 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Antineoplastics; Capecitabine; Fluorouracil; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Expanded access
  • Acronyms BEAT; First-BEAT
  • Sponsors Roche
  • Most Recent Events

    • 02 Aug 2011 New source identified and integrated (European Clinical Trials Database).
    • 23 Sep 2009 Results were presented at the Joint 15th European Cancer Conference (ECCO) and the 34th Congress of the European Society for Medical Oncology (ESMO), held in Berlin, Germany.
    • 12 Sep 2008 Results for the final overall survival analysis reported at ESMO 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top